CD36 and breast carcinoma: In addition, analysis of data from the NeoALTTO trial showed that CD36 increased in HER2-positive breast cancer after treatment with lapatinib and trastuzumab in the neoadjuvant setting and it was correlated with poor prognosis[57] [Table 2].